Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): An Aggressive Disease Course and Limitations for Personalized Oncology

Oncology and Therapy · Published 2026-06-25 · DOI 10.1007/s40487-026-00454-7

Free full text

Authors (7)

Celine Oanæs, Herish Garresori, Dordi Lea, Marcus T. T. Roalsø, Torjan M. Haslerud, Cato Brede, Kjetil Søreide

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Oanæs, C., Garresori, H., Lea, D., et al. (2026). Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): An Aggressive Disease Course and Limitations for Personalized Oncology. Oncology and Therapy. https://doi.org/10.1007/s40487-026-00454-7

Related articles

• Abemaciclib Persistence in Patients with HR+, HER2−, Node-Positive Early Breast Cancer: a Real-World Analysis · Oncology and Therapy · 2025 · Same journal
• A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia · Oncology and Therapy · 2026 · Same journal
• The Immuno-oncology-Induced Cytokine Release Syndrome Patient Diary: A Content-Valid, Patient-Reported Outcome Measure · Oncology and Therapy · 2025 · Same journal
• Expression of Prostate-Specific Membrane Antigen in Salivary Gland Tumors · Oncology and Therapy · 2025 · Same journal
• Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer · Oncology and Therapy · 2025 · Same journal
• Real-World Epidemiology, Clinical Characteristics and Outcomes of Women with Germline BRCA Mutation and Early Breast Cancer in China · Oncology and Therapy · 2025 · Same journal
• Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England · Oncology and Therapy · 2025 · Same journal
• Qualitative Interviews on the Experience of Orally vs. Intramuscularly Administered Endocrine Therapy for Advanced Breast Cancer: Patient and Healthcare Provider Perspectives · Oncology and Therapy · 2025 · Same journal
• Patient and Physician Perspectives on Multiple Myeloma Data Presented at ASCO and EHA 2025: A Podcast · Oncology and Therapy · 2025 · Same journal
• Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology · Oncology and Therapy · 2026 · Same journal